Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, Jianjun, Shi, Lewis Zhichang, Zhao, Hao, Chen, Jianfeng, Xiong, Liangwen, He, Qiuming, Chen, Tenghui, Roszik, Jason +8 more·2016·Cell

DOI 10.1016/j.cell.2016.08.069

Cited by (1,000)

Items 501–600 of 1,000

Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan‐cancer survey with implications for the use of immune checkpoint inhibitors
Jan Budczies, Michael Ludwig Bockmayr, Frederick Klauschen, Volker Endris, Stefan Fröhling, Peter Schirmacher, Carsten Denkert, Albrecht Stenzinger · 2017 · Genes Chromosomes and Cancer
ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma
Takeshi Fukumoto, Jianhuang Lin, Nail Fatkhutdinov, Pingyu Liu, Rajasekharan Somasundaram, Meenhard Herlyn, Rugang Zhang, Chikako Nishigori · 2020 · Journal of Investigative Dermatology
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Yin Wu, Dhruva Biswas, Charles Swanton · 2021 · Seminars in Cancer Biology
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Allan Relecom, Maysaloun Merhi, Varghese Philipose Inchakalody, Shahab Uddin M.S., Darawan Rinchai, Davide Bedognetti, Said Dermime · 2021 · Journal of Experimental & Clinical Cancer Research
The Abscopal Effect in the Era of Checkpoint Inhibitors
Ondřej Kodet, Kristýna Němejcová, Karolína Strnadová, Andrea Havlínová, Pavel Dundr, Ivana Krajsová, Jiří Štork, Karel Smetana, Lukáš Lacina · 2021 · International Journal of Molecular Sciences
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
Danielle C. Kirkey, Anisha M. Loeb, Sommer Castro, Cyd Nourigat McKay, LaKeisha Perkins, Laura M. Pardo, Amanda R. Leonti, Thao T. Tang, Michael R. Loken, Lisa Eidenschink Brodersen et al. · 2022 · Blood Advances
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, Rotem Leshem, Wei Zhang, Vishaka Gopalan, Sorayut Chattrakarn, Macarena Lucia Fernandez Carro, Erez Uzuner, Holly Mole et al. · 2023 · Nature Communications
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers
Areti D. Strati, Christos Adamopoulos, Ioannis Kotsantis, Amanda K. Psyrri, Evi S. Lianidou, Athanasios G. Papavassiliou · 2025 · International Journal of Molecular Sciences
Checkpoint Inhibitors: Applications for Autoimmunity
Anna S. Tocheva, Adam Mor · 2017 · Current Allergy and Asthma Reports
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
Marine Leclerc, Laura Mezquita, Guillaume Guillebot De Nerville, Isabelle Tihy, Ines Malenica, Salem Chouaı̈b, Fathia Mami‐Chouaib · 2019 · Frontiers in Immunology
Targeting Histone Deacetylase 6 Reprograms Interleukin‐17‐Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma
Weinan Qiu, Bin Wang, Yanan Gao, Yuan Tian, Meijie Tian, Yuanying Chen, Li ming Xu, Tso‐Pang Yao, Peng Li, Pengyuan Yang · 2019 · Hepatology
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
Shuling Zhang, Xueli Bai, Fengping Shan · 2020 · International Immunopharmacology
Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Tomasz M. Grzywa, Magdalena Justyniarska, Dominika Nowis, Jakub Gołąb · 2021 · Cancers
Epithelial-to-mesenchymal transition hinders interferon-γ-dependent immunosurveillance in lung cancer cells
Po‐Chun Tseng, Chia‐Ling Chen, Kang-Yuan Lee, Po‐Hao Feng, Yu‐Chih Wang, Rahmat Dani Satria, Chiou‐Feng Lin · 2022 · Cancer Letters
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Ishita Gupta, Ola Hussein, Konduru Seetharama Sastry, Salim Bougarn, Neha Gopinath, Evonne C. Chin-Smith, Yashi Sinha, Hesham Mohamed Korashy, Cristina Maccalli · 2023 · Advances in Cancer Biology - Metastasis
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy
Yi Bao, Yuanyuan Qiao, Jae Eun Choi, Yuping Zhang, Rahul Mannan, Caleb Cheng, Tongchen He, Yang Zheng, Jiali Yu, Mahnoor Naseer Gondal et al. · 2023 · Proceedings of the National Academy of Sciences
Gut microbiota Parabacteroides distasonis enchances the efficacy of immunotherapy for bladder cancer by activating anti-tumor immune responses
Benlin Wang, Yifeng Qiu, Ming Xie, Pengcheng Huang, Yao Yu, Qi Sun, Wentai Shangguan, Weijia Li, Zhangrui Zhu, Jingwen Xue et al. · 2024 · BMC Microbiology
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
Yaqi Li, Jing Liu, Long Gao, Yuan Liu, Fang Meng, Xiaoan Li, Frank Xiao-Feng Qin · 2019 · Immunology Letters
Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-beltran B, Liang Cheng C, Nicola Battelli, Rodolfo Montironi et al. · 2019 · Cancers
Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy
Yuequan Shi, Xiaoyan Liu, Juan Du, Dongming Zhang, Jia Liu, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang · 2021 · Thoracic Cancer
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna L. K. Gonye, Arvind Ravi, Monica B. Arniella, Irena Gushterova, Thomas James LaSalle, Emily M. Blaum et al. · 2022 · Cell Reports Medicine
ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line
Kazem Zibara, Asad Zeidan, Hassan Bjeije, Nouhad A. Kassem, Bassam M. Badran, Nabil El Zein · 2016 · Journal of Cell Communication and Signaling
DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Yipeng Song, Jian Ping Huang, Dandan Liang, Ying Hu, Beibei Mao, Qiujing Li, Huaibo Sun, Ying Yang, Jiao Zhang, Henghui Zhang et al. · 2021 · Frontiers in Oncology
Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
Chen Jie, Rumeng Li, Yajie Cheng, Zhihao Wang, Qiuji Wu, Conghua Xie · 2023 · Frontiers in Immunology
MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
Juan J. Alburquerque-Béjar, Pablo Navajas-Chocarro, Maria Saigí, Ana Ferrero-Andres, Juan M. Morillas, Andrea Vilarrubi, Antonio Gómez, José Luís Mate, Ana María Muñoz-Mármol, Octavio A. Romero et al. · 2023 · Cell Reports Medicine
T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy
Aida S. Hansen, Lea S. Jensen, Kristine Raaby Gammelgaard, Kristoffer G. Ryttersgaard, Christian Krapp, Jesper Just, Kasper L. Jønsson, Pia Bomholt Jensen, Thomas P. Boesen, Mogens Johannsen et al. · 2023 · Journal of Extracellular Vesicles
The spread of interferon-γ in melanomas is highly spatially confined, driving nongenetic variability in tumor cells
Edoardo Centofanti, Chad Wang, Sandhya Iyer, Oleg Krichevsky, Alon Oyler‐Yaniv, Jennifer E. Oyler · 2023 · Proceedings of the National Academy of Sciences
Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer
Yuan Jiang, Yueyuan Zheng, Yuan‐Wei Zhang, Shuai Kong, Jinxiu Dong, Fei Wang, Benjamin Ziman, Sigal Gery, Jia‐Jie Hao, Dan Zhou et al. · 2024 · Nature Communications
Interferon Signaling Is Frequently Downregulated in Melanoma
Sara Alavi, Ashleigh Stewart, Richard F. Kefford, Su Yin Lim, Elena Shklovskaya, Helen Rizos · 2018 · Frontiers in Immunology
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy
Bartosz Szostak, Filip Machaj, Jakub Rosik, Andrzej Pawlik · 2018 · Expert Opinion on Investigational Drugs
Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties
Martha Baydoun, Olivier Moralès, Céline Frochot, Ludovic Colombeau, Bertrand Leroux, Elise Thécua, Laurine Ziane, Anne Grabarz, Kumar Abhishek, Clémentine de Schutter et al. · 2020 · Journal of Clinical Medicine
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell, Lorenzo Galluzzi · 2017 · OncoImmunology
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Alice Indini, Daniela Massi, Matteo Pirro, Fausto Roila, Francesco Grossi, Amirhossein Sahebkar, Nicole Glodde, Tobias Bald, Mario Mandalà · 2022 · Seminars in Cancer Biology
Epigenetic mechanisms of tumor resistance to immunotherapy
Arenas-Ramirez, Natalia, Sahin, Dilara, Boyman, Onur · 2018 · Cellular and Molecular Life Sciences
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Son Hai Vu, Preethi Vetrivel, Jongmin Kim, Myeong‐Sok Lee · 2022 · International Journal of Molecular Sciences
Challenges and solutions for therapeutic TCR ‐based agents
Manish Malviya, Zita E. H. Aretz, Zaki Molvi, Jaeyop Lee, Stephanie A. Pierre, Patrick Wallisch, Tao Dao, David A. Scheinberg · 2023 · Immunological Reviews
Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer
Hao Yuan, Xingning Mao, Yunkun Yan, Rong Huang, Qingyun Zhang, Yanyu Zeng, Mengying Bao, Yan Dai, Bo Fang, Junhao Mi et al. · 2024 · Journal of Translational Medicine
Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
Yara George Abdou, Manu Raj Pandey, Maithreyi Sarma, Shrunjal Shah, Jeffrey I. Baron, Marc S. Ernstoff · 2020 · British Journal of Clinical Pharmacology
Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade
Zicheng Zhang, Hongyan Chen, Dongxue Yan, Lu Chen, Jie Sun, Meng Zhou · 2023 · Oncogenesis
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
Rachel S. Goodman, Seungyeon Jung, Justin Micah Balko, Douglas Buckner Johnson · 2023 · Immunological Reviews
Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity
Huan Liu, Wenyong Yang, Jingwen Jiang · 2024 · Journal of Pharmaceutical Analysis
Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease
Jingyi Duan, Qinmei Li, Yan Cheng, Weifeng Zhu, Hongning Liu, Fei Li · 2024 · MedComm
Current Options and Future Directions in Immune Therapy for Glioblastoma
John P. Lynes, Victoria Sánchez, Gifty A. Dominah, Anthony Nwankwo, Edjah Kweku-Ebura Nduom · 2018 · Frontiers in Oncology
neoepiscope improves neoepitope prediction with multivariant phasing
Mary Ann Wood, Austin Nguyen, Adam J. Struck, Kyle Ellrott, Abhinav Nellore, Reid F. Thompson · 2019 · Bioinformatics
Calreticulin is a Critical Cell Survival Factor in Malignant Neoplasms
Arum Han, Chen Li, Tara Zahed, M K Wong, Ian F. Smith, Karl Hoedel, Douglas R. Green, Alexander D. Boiko · 2019 · PLoS Biology
Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF-κB Pathways
Xinping Yang, Hui Wen Cheng, Jianhong Chen, Ru Wang, Anthony D. Saleh, Han Si, Steven S. Lee, Emine Guven‐Maiorov, Özlem Keskin, Attila Gürsoy et al. · 2019 · Cancer Immunology Research
Advances in theranostic biomarkers for tumor immunotherapy
Audrey Bellesœur, Nouritza Torossian, Sebastián Amigorena, Emanuela Romano · 2020 · Current Opinion in Chemical Biology
A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
Weinan Guo, Jinyuan Ma, Sen Guo, Huina Wang, Sijia Wang, Qiong Shi, Lin Liu, Tao Zhao, Fengfan Yang, Shuyang Chen et al. · 2020 · Journal for ImmunoTherapy of Cancer
Epigenetic modulation of immunotherapy and implications in head and neck cancer
Liye Zhou, Na Xu, Hirofumi Shibata, Vassiliki Saloura, Ravindra Uppaluri · 2021 · Cancer and Metastasis Reviews
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
Lucas Vieira dos Santos, Carina Meira Abrahão, William N. William · 2021 · Frontiers in Oncology
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
Xi Jiao, Xin Lan Wei, Shuang Li, Chang Xin Liu, Huan Chen, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng et al. · 2021 · npj Precision Oncology
Guide Positioning Sequencing identifies aberrant DNA methylation patterns that alter cell identity and tumor-immune surveillance networks
Jin Li, Yan Li, Wei Li, Huai-Bing Luo, Yan-Ping Xi, Shi-Hua Dong, Ming Gao, Peng Xu, Bao-Long Zhang, Ying Liang et al. · 2019 · Genome Research
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Jun Ho Ji, Sang Yun Ha, Danbi Lee, K. Nathan Sankar, Ekaterina K. Koltsova, Ghassan K. Abou‐Alfa, Ju Dong Yang · 2023 · International Journal of Molecular Sciences
Interferon signaling pathways in health and disease
Chunli Wen, Qingzhan Lan, Yunshan Wang, Yang Ni, Alice S.T. Wong, Duanrui Liu · 2025 · Molecular Biomedicine
The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
Ri‐Yao Yang, Mien‐Chie Hung · 2017 · Science China Life Sciences
Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers
Ian MacFawn, Hannah E. Wilson, Luke A. Selth, Ian A. Leighton, Ilya G. Serebriiskii, R. Christopher Bleackley, Osama M. Elzamzamy, Joshua C. Farris, Phillip M. Pifer, Jennifer K. Richer et al. · 2018 · Molecular Immunology
Therapeutic Development of Immune Checkpoint Inhibitors
Jilin Wang, Teddy Yang, Jie Xu · 2020 · Advances in experimental medicine and biology
FIP200 Suppresses Immune Checkpoint Therapy Responses in Breast Cancers by Limiting AZI2/TBK1/IRF Signaling Independent of Its Canonical Autophagy Function
Takako Okamoto, Syn Kok Yeo, Mingang Hao, Mary Rose Copley, Michael A. Haas, Song Chen, Jun‐Lin Guan · 2020 · Cancer Research
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
Soleine Medjebar, Caroline Truntzer, Anaïs Perrichet, Emeric Limagne, Jean-David Fumet, Corentin Richard, Arielle Elkrief, Bertrand Routy, Cédric Rébé, François Ghiringhelli · 2020 · OncoImmunology
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
Julie Vackova, Ingrid Poláková, Shweta Dilip Johari, Michal Šmahel · 2021 · Cancers
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity
Andy Karabajakian, Jebrane Bouaoud, Lucas Michon, Maud T Kamal, Carole Crozes, Philippe Zrounba, Jessie Auclair, Nicolas Gadot, Valéry Attignon, Christophe Le Tourneau et al. · 2021 · Oral Oncology
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
Omar Alhalabi, Yueting Zhu, Ameer Hamza, Wei Qiao, Yiyun Lin, Raymond M. Wang, Amishi Yogesh Shah, Matthew T. Campbell, Vijaykumar R. Holla, Ashish M. Kamat et al. · 2021 · European Urology Oncology
Interferon Signaling in Estrogen Receptor–positive Breast Cancer: A Revitalized Topic
Xiaoyong Fu, Carmine De Angelis, Rachel Schiff · 2021 · Endocrinology
Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
Yanhao Liu, Yan Xu, Xi Cheng, Yaru Lin, Shu Jiang, Haiming Yu, Zhen Zhang, Linlin Lu, Xiaotao Zhang · 2022 · Frontiers in Immunology
Immune Resistance Mechanisms and the Road to Personalized Immunotherapy
Miles Piper, Harriet M. Kluger, Eytan Ruppin, Siwen Hu‐Lieskovan · 2023 · American Society of Clinical Oncology Educational Book
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Junghwa Lee, Eui Ho Kim · 2023 · Frontiers in Oncology
LNK suppresses interferon signaling in melanoma
Ling‐Wen Ding, Qiao‐Yang Sun, Jarem J. Edwards, Lucia Torres Fernández, Xue‐Bin Ran, Siqin Zhou, Richard A. Scolyer, James S. Wilmott, John F. Thompson, Ngan Doan et al. · 2019 · Nature Communications
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
Eric Song, Ryan Dz-Wei Chow · 2023 · Cancer Cell
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
Miles Cameron Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer Ann Wargo · 2018 · Frontiers in Immunology
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer
Luigi Perelli, Federica Carbone, Li Zhang, Justin Kwang-Lay Huang, Courtney N. Le, Hania Khan, Francesca Citron, Edoardo Del Poggetto, Tony Gutschner, Hideo Tomihara et al. · 2023 · Nature Cancer
Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway
Xiaobo Luo, Yan Qiu, Zackary R. Fitzsimonds, Qiuhao Wang, Qianming Chen, Yu L. Lei · 2024 · Oncogene
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives
Manman Lu, Yu Yang · 2024 · Frontiers in Immunology
Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes
Hiroko Tadokoro, Akiyoshi Hirayama, Ryuhei Kudo, Masako Hasebe, Yusuke Yoshioka, Juntaro Matsuzaki, Yusuke Yamamoto, Masahiro Sugimoto, Tomoyoshi Soga, Takahiro Ochiya · 2020 · PLoS ONE
Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade
Annette Paschen, Ignacio Melero, Antoni Ribas · 2021 · Annual Review of Cancer Biology
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Marzieh Nikoo, Fatemeh Rabiee, Hossein Mohebbi, Negar Eghbalifard, Hamid Rajabi, Yalda Yazdani, Delaram Sakhaei, Mohammadreza Khosravifarsani, Reza Akhavan‐Sigari · 2023 · International Immunopharmacology
Epigenetic Regulation of Immune Checkpoints: Another Target for Cancer Immunotherapy?
MAHMOUD A.M. ALI, Marwa Matboli, Marwa Tarek, Maged Reda, Kamal M. Kamal, Mahmoud Nouh, Ahmed M Ashry, Ahmed Fath El-Bab, Hend A Mesalam, Ayman Shafei et al. · 2016 · Immunotherapy
Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis
Wei‐Guo Tang, Bo Hu, Haixiang Sun, Qi‐Man Sun, Chao Sun, Pei‐Yao Fu, Zhangfu Yang, Xin Zhang, Chenhao Zhou, Jia Fan et al. · 2017 · Oncotarget
PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review
Jen Chin C. Wang, Lishi Sun · 2022 · International Journal of Molecular Sciences
Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
Wenzhe Yi, Dan Yan, Dangge Wang, Yaping Li · 2023 · Cancer Biology and Medicine
The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
Chun Wai Wong, Yang Huang, Adam F. L. Hurlstone · 2023 · Essays in Biochemistry
Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial
Alexander Dean Sherry, Bilal Ahmed Siddiqui, Cara Haymaker, Bryan M. Fellman, Marina Nayeli Medina-Rosales, Tharakeswara Kumar Bathala, Shuqi Wang, Suyu Liu, Aaron Seo, Kieko Hara et al. · 2025 · European Urology
HER2 and urothelial carcinoma: current understanding and future directions
Daniele Raggi, Emanuele Crupi, Filippo Pederzoli, Alberto Martini, Alberto Briganti, Omar Alhalabi, Peter H. O’Donnell, Jeffrey S. Ross, Shilpa Gupta, Ashish M. Kamat et al. · 2025 · Nature Reviews Urology
TYK2 in Tumor Immunosurveillance
Anzhelika Karjalainen, Stephen Shoebridge, Milica Krunic, Natalija Simonović, Graham Tebb, Sabine Macho‐Maschler, Birgit Strobl, Mathias M. Müller · 2020 · Cancers
Human T cells employ conserved AU‐rich elements to fine‐tune IFN‐γ production
Julian J. Freen‐van Heeren, Branka Popović, Aurélie Guislain, Monika C. Wolkers · 2020 · European Journal of Immunology
Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
Gitte Holmen Olofsson, Agnete W.P. Jensen, Manja Idorn, Per thor Straten · 2020 · International Journal of Molecular Sciences
Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages
Julio C. Valencia, Rebecca A. Erwin-Cohen, Paúl E. Clavijo, Clint Allen, Michael E. Sanford, Chi-Ping Day, Megan M. Hess, Morgan Johnson, Jie Yin, John M. Fenimore et al. · 2021 · Cancer Research
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Brian Bird, Kenneth Nally, Karine E. Ronan, Gerard A. Clarke, Sylvie Amu, Ana Santos Almeida, Richard Flavin, Stephen P. Finn · 2022 · Diagnostics
Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity
Julie Magarian Blander · 2023 · Seminars in Immunology
Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway
Chiara Massa, Yuan Wang, Nico Marr, Barbara Seliger · 2023 · International Journal of Molecular Sciences
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Rachel Su Jen Wong, Rebecca Jia Min Ong, Joline SJ Lim · 2023 · Cancer Drug Resistance
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Ginette S. Santiago-Sánchez, Kellsye P. Fabian, James W. Hodge · 2024 · Cancer Biology & Therapy
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets
Tomáš Hofman, Siu Wang Ng, Irene Garcés-Lázaro, Florian Heigwer, Michael Boutros, Adelheid Cerwenka · 2024 · Journal for ImmunoTherapy of Cancer
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Magdalena K. Zielińska, Magdalena A. Ciążyńska, Dorota Sulejczak, Piotr Lukasz Rutkowski, Anna Malgorzata Czarnecka · 2025 · Biomolecules
Immunotherapy in colorectal cancer
Parul Agarwal, Dung Thi Le, Patrick McKay Boland · 2021 · Advances in cancer research
Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer
Hao Chen, Wei Chong, Xiaorong Yang, Yuan Zhang, Shaowei Sang, Xiangchun Li, Ming Lü · 2020 · OncoImmunology
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
Shengqing Stan Gu, Xiaoqing Wang, Xihao Sherlock Hu, Peng Jiang, Ziyi Li, Nicole C. Traugh, Xia Bu, Qin Tang, Chenfei Wang, Zexian Zeng et al. · 2020 · Genome biology
Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma
Yuxiang Ma, Xi Chen, Ao Wang, Hongyun Zhao, Qingguang Lin, Hua Bao, Yang Zhang, Shaodong Hong, Wanxiangfu Tang, Yan Huang et al. · 2021 · Journal for ImmunoTherapy of Cancer
Multiomics analysis of tumor mutational burden across cancer types
Lin Li, Long Bai, Huan Lin, Lin Dong, Rumeng Zhang, Xiao Cheng, Zexian Liu, Yi Qin Ouyang, Keshuo Ding · 2021 · Computational and Structural Biotechnology Journal
A mouse model of the LEAP study reveals a role for CTLA-4 in preventing peanut allergy induced by environmental peanut exposure
James Walter Krempski, Jyoti K. Lama, Koji Iijima, Takao Kobayashi, Mayumi Matsunaga, Hirohito Kita · 2022 · Journal of Allergy and Clinical Immunology
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
Ericka M. Ebot, Daniel L. Duncan, Khaled A. Tolba, David A. Fabrizio, Garrett Michael Frampton, Leah A. Comment, Lee A. Albacker · 2022 · npj Precision Oncology